» Articles » PMID: 34490820

SNU-333 Cells As an Appropriate Cell Line for the Orthotopic Renal Cell Carcinoma Model

Overview
Date 2021 Sep 7
PMID 34490820
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

: To investigate a feasible candidate for an appropriate cell line for the orthotopic renal cell carcinoma (RCC) model. Normal human proximal tubule cells (HK-2) and RCC cells were used for MTT assay, Western blotting, sphere-forming assay, and orthotopic injection of BALB/c-nude mice. Immunohistochemistry was adopted in tissue arrays and orthotopic tumors. Primary RCC cells showed resistance to a GPX4 inhibitor compared to HK-2 and to metastatic RCC cells, Caki-1. Caki-2 and SNU-333 cells showed resistance to ferroptosis via increased GPX4 and FTH1, respectively. RCC cells showed increased αSMA, in which Caki-2 and SNU-333 cells exhibited different epithelial-mesenchymal transition and cancer stem cell markers. Caki-1 and SNU-333 cells formed spheres in vitro and orthotopic tumor masses in vivo. The injected SNU-333 tumor only showed high intensities of CD10 and PAX8, markers of renal origin. SNU-333 cell line exhibited resistance via iron metabolism and stemness, and had tumor-initiating capacities in vitro and in vivo. These results suggest that among the cells tested, SNU-333 cells were the most promising for the establishment of an orthotopic RCC model for further researches.

Citing Articles

The significance of ferroptosis in renal diseases and its therapeutic potential.

Jiang M, Wu S, Xie K, Zhou G, Zhou W, Bao P Heliyon. 2024; 10(16):e35882.

PMID: 39220983 PMC: 11363859. DOI: 10.1016/j.heliyon.2024.e35882.


Increased soluble E‑cadherin of spheroid formation supplemented with fetal bovine serum in colorectal cancer cells.

Chang I, Yoon S Oncol Lett. 2023; 25(5):207.

PMID: 37123020 PMC: 10131269. DOI: 10.3892/ol.2023.13793.

References
1.
Moon D, Kim J, Yoon S . Yeast extract inhibits the proliferation of renal cell carcinoma cells via regulation of iron metabolism. Mol Med Rep. 2019; 20(4):3933-3941. DOI: 10.3892/mmr.2019.10593. View

2.
Pfeifhofer-Obermair C, Tymoszuk P, Petzer V, Weiss G, Nairz M . Iron in the Tumor Microenvironment-Connecting the Dots. Front Oncol. 2018; 8:549. PMC: 6275298. DOI: 10.3389/fonc.2018.00549. View

3.
Corro C, Moch H . Biomarker discovery for renal cancer stem cells. J Pathol Clin Res. 2018; 4(1):3-18. PMC: 5783955. DOI: 10.1002/cjp2.91. View

4.
Shibue T, Weinberg R . EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017; 14(10):611-629. PMC: 5720366. DOI: 10.1038/nrclinonc.2017.44. View

5.
Toth C, Funke S, Nitsche V, Liverts A, Zlachevska V, Gasis M . The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling. Cell Commun Signal. 2017; 15(1):16. PMC: 5414156. DOI: 10.1186/s12964-017-0170-5. View